Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes

Gorantla V Raghuram1,2, Kavita Pal1,2, Gaurav Sriram1,2

  • 1Translational Research Laboratory, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India.

Plos One
|February 12, 2024
PubMed

Insights

Cancer treatments may release cell-free chromatin particles (cfChPs) that spread cancer. These oncogenic particles can transform healthy cells into new tumors, mimicking metastasis. However, deactivating cfChPs can prevent this spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis Research

Background:

  • Metastatic dissemination remains a primary cause of cancer-related death.
  • Therapeutic interventions for primary tumors may paradoxically promote metastatic disease.
  • Previous research identified cell-free chromatin particles (cfChPs) from dying cancer cells as potentially oncogenic.

Purpose of the Study:

  • To investigate the hypothesis that therapeutic interventions release oncogenic cfChPs.
  • To determine if these cfChPs can disseminate via bloodstream and induce secondary tumors.
  • To explore methods for preventing cfChP-mediated cancer spread.

Main Methods:

  • Xenografts of MDA-MB-231 human breast cancer cells in severe combined immune-deficient mice.
  • Immuno-fluorescence and FISH analysis to detect human cfChPs in mouse brain cells.
  • Assessment of cfChP levels following chemotherapy, radiotherapy, or surgery, with and without cfChP deactivating agents.

Main Results:

  • Human DNA signals (cfChPs) co-localizing with human oncoproteins were detected in mouse brain cells.
  • No intact human cancer cells were found in the brain.
  • Chemotherapy, radiotherapy, and surgery significantly increased cfChP signals, which was preventable by cfChP deactivating agents.

Conclusions:

  • Therapeutic interventions release oncogenic cfChPs from dying cancer cells.
  • These cfChPs are transported via the bloodstream to distant sites like the brain.
  • Concurrent treatment with cfChP deactivating agents can prevent therapy-induced metastatic spread.